Search

Objectives: 1.- To know the risk of detectable Prostate Cancer (PC) and significant PC by applying a Risk Calculator to patients who underwent a prostate biopsy (PB) and to analyze if there are significant differences between the risk of patients who had positive versus negative biopsies. 2.- To compare the risk of those patients with positive results who were detected in the first biopsies vs re-biopsies. 3.- To compare our results with those obtained if we had applied the cut points established in the CP risk calculator., Methods: Through a retrospective descriptive analytical study, we studied 496 prostate biopsies (PB) performed during 3 years (2014-2016), applying the SWOP risk calculator, analyzing if there are significant differences between those patients who had a positive vs negative result and those submitted to re-biopsies., Results: The mean risk of detectable PC by the calculator for positive PB was 34.98% versus 24.71% of negative PB; in relation to the risk of significant PC, for positive PB it was 19.13% versus 8.8% of the negative PB, with significant differences (p<0.01) in both comparisons. When patients were grouped by first biopsies vs re-biopsies, we observed that patients with the first positive biopsy had an estimated risk by the calculator of 44% compared to 31% of the first negative prostate biopsies, this difference being statistically significant., Conclusions: The application of a prostate cancer risk calculator in candidates for first biopsy allows optimization of the test, although it loses effectiveness in patients with previous negative PB.

Introduction: Prostate re-biopsydoes not guarantee detection of prostate cancer(PC), sometimes leading to overdiagnosis of clinicallyinsignificant tumors. The present study shows theincidence of PC in our hospital and analyzes thedistribution of risk groups and prognosis depending inthe diagnosis obtained by first biopsy vs rebiopsy., Objectives: 1. To know the incidence of ProstateCancer (PC) in patients biopsied in our hospital duringthe years 2014, 2015 and 2016 as well as thedistribution by risk and prognosis groups.2. To know if there are significant differences in thedistribution of risk and prognostic groups among patientsdiagnosed of PC by first biopsy vs rebiopsies in ourhospital in the years 2014, 2015 and 2016., Materials and Methods: A longitudinal retrospectivedescriptive and analytical study was performed with496 patients undergoing prostate biopsy (PB) in ourhospital between January 1st 2014 and December31st 2016. We analyze the results of prostate biopsy,Gleason score and distribution by prognosis group toverify if there were significant differences between firstbiopsy vs prostate biopsy., Results: The rate of positive PB in first biopsy was38.3% compared to 26.8% in rebiopsy. There weresignificant differences (p=0.01). In our series wediagnosed in first biopsy 71.8% of significant PC andthe 90% of the of bad or very bad prognosis PC (groups4 and 5 according to the ISUP classification)., Conclusions: There are significant differences inthe diagnosis of prostate cancer between a first biopsyand a rebiopsy. Tumors diagnosed by rebiopsies havea better prognosis than those diagnosed by first biopsy.We must adopt mechanisms to increase the diagnosticyield of re-biopsies.

50 year old male with history of renal colic presenting to the emergency room with left colic pain. On ultrasound horseshoe kidneys were visualized without hydronephrosis or stones. CT scan: horseshoe kidney with inferior isthmus, no signs of nephrolithiasis or urolithiasis. There are multiple associated vascular anomalies (there are at least five right renal arteries and two left, double venous return is seen in both hemi-kidneys).